封面
市场调查报告书
商品编码
1553540

美国复合药房市场规模、份额和趋势分析报告:按类型、治疗领域、年龄组、复合类型、无菌性别、细分市场预测,2024-2030

U.S. Compounding Pharmacies Market Size, Share, & Trends Analysis Report By Type (503A, 503B), By Therapeutic Area, By Age Cohort, Compounding Type, By Sterility, And Segment Forecasts, 2024 - 2030

出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

美国复合药局市场成长与趋势:

根据Grand View Research, Inc.最新报告显示,到2030年,美国复方药品市场规模预计将达71.8亿美元,并预计2024年至2030年复合年增长率为4.89%。

由于对组合药物的认识和采用的提高,预计该市场将显着增长。需求增加的原因是处方量增加、药品短缺频繁、关键药品停产。这些短缺,再加上供应链中断和因 COVID-19 大流行而加剧的製造延迟问题,增加了复方药房的关键作用。

FDA 表示,由于生产限制、原材料短缺和物流延误,疫情期间药品短缺加剧。因此,复方药局有更多的机会来填补这些药品短缺。 FDA 甚至发布了临时指南,允许联邦和州许可的药房在突发公共卫生事件期间为住院患者配製某些药物。需求成长和监管支持的结合预计将推动市场扩张。

美国复合製药市场报告亮点:

  • 按类型划分,503A 细分市场在 2023 年占据最大收益占有率。这是由于对个别患者需求的个人化药物的需求不断增加。
  • 按治疗领域划分,疼痛管理细分市场由于其专门的方法来减轻标准疼痛管理药物的副作用,因此在 2023 年占据最大的市场占有率。
  • 按年龄层划分,成人市场在 2023 年占据最大收益占有率。这是由于过敏、特定剂量要求以及对其他形式药物的偏好等因素所造成的。
  • 以复方类型划分,由于有特殊需求的患者对定製药物的需求量很大,药物成分改变(PIA)领域在 2023 年将主导美国复方药房市场。
  • 以无菌为基础,由于老年和小儿科患者对静脉注射无菌方案的巨大需求,无菌细分市场在 2023 年占据了最大的销售份额,占据了市场主导地位。
  • 例如,2023年2月,美国着名眼科保健製药公司Harrow Health, Inc.推出了正在申请专利的下一代组合阿托品配方。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场趋势及展望
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 营商环境分析
    • 产业分析-波特五力分析
    • PESTEL分析

第四章按类型分類的业务分析

  • 按类型细分仪表板
  • 美国复合药品市场:按类型波动分析
  • 2018-2030 年美国复合製药市场规模及趋势分析(按类型)
  • 503A
    • 503A市场,2018-2030
  • 503B
    • 503B市场,2018-2030

第五章 治疗领域业务分析

  • 按治疗领域细分仪表板
  • 美国复合药局市场:治疗面积波动分析
  • 2018-2030 年美国复方製药市场规模及趋势分析(依治疗领域)
  • 疼痛管理
    • 疼痛管理市场,2018-2030
  • 荷尔蒙补充疗法
    • 荷尔蒙补充疗法市场,2018-2030
  • 特种药品
    • 特种药品市场,2018-2030
  • 皮肤科
    • 皮肤科市场,2018-2030
  • 食品补充品
    • 营养食品市场,2018-2030
  • 其他的
    • 其他市场,2018-2030

第 6 章按年龄组别分類的业务分析

  • 按年龄组别细分仪表板
  • 美国复合药局市场:依年龄族群变化分析
  • 2018-2030 年美国复方药品市场规模与趋势分析(依年龄层)
  • 儿科的
    • 儿科市场,2018-2030
  • 成人
    • 成人市场,2018-2030
  • 老年人
    • 老年人市场,2018-2030

第 7 章复利业务分析

  • 透过复合细分仪表板
  • 美国复合药品市场:按复合类型的波动分析
  • 2018-2030年美国复方製药市场规模及趋势分析(依复方类型)
  • 药物成分变化(PIA)
    • 药物成分变更 (PIA) 市场,2018-2030
  • 目前无法使用的药品製造 (CUPM)
    • 目前无法使用的药品製造 (CUPM) 市场,2018-2030 年
  • 药物剂量变更 (PDA)
    • 药物剂量改变 (PDA) 市场,2018-2030

第八章 不孕性业务分析

  • 无菌性别细分仪表板
  • 美国复合药局市场:无菌性别差异分析
  • 美国复合製药市场规模及趋势分析,不孕性别,2018-2030
  • 无菌的
    • 灭菌市场,2018-2030
  • 非无菌
    • 非无菌市场,2018-2030

第9章 竞争格局

  • 公司分类
  • 公司市场分析
  • 策略规划
  • 公司简介/上市公司
    • Avella Specialty Pharmacy
    • Central Admixture Pharmacy Services, Inc.
    • Clinigen Limited
    • Fagron
    • Fresenius Kabi USA
    • ImprimisRx(Harrow Health, Inc.)
    • PenCol Pharmacy
    • Sixth Avenue Medical Pharmacy
    • Triangle Compounding
    • Vertisis Custom Pharmacy
Product Code: GVR-4-68040-422-9

U.S. Compounding Pharmacies Market Growth & Trends:

The U.S. compounding pharmacies market size is anticipated to reach USD 7.18 billion by 2030 and is anticipated to grow at a CAGR of 4.89% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is poised for substantial growth, driven by rising awareness and adoption of compounded medications. The growing demand stems from increasing prescription volumes, frequent drug shortages, and manufacturer discontinuations of key medications. These shortages, impaired by supply chain disruptions and manufacturing delays issues that were intensified by the COVID-19 pandemic have increased the critical role of compounding pharmacies.

According to the FDA, drug shortages increased due to manufacturing restrictions, raw material shortages, and logistic delays during the pandemic. As a result, compounding pharmacies gained more opportunities to fill these gaps in drug availability. The FDA even issued temporary guidance allowing federally and state-licensed pharmacies to compound certain medications for hospitalized patients during public health emergencies. This combination of rising demand and regulatory support is expected to drive market expansion.

U.S. Compounding Pharmacies Market Report Highlights:

  • Based on type, the 503A segment held the largest revenue share in 2023. This is attributed to the rising demand for personalized medications tailored to individual patient needs.
  • Based on therapeutic area, the pain management segment dominated the market with the largest market share in 2023 due to its specialized approaches in alleviating the side effects of standard pain management medications.
  • Based on age cohort, the adult segment dominated the market with the largest revenue share in 2023 due to factors such as allergies, specific dosage requirements, and preferences for other forms of medication.
  • Based on compounding type, the pharmaceutical ingredient alteration (PIA) segment dominated the U.S. compounding pharmacies market in 2023 due to the high demand for customized drugs from patients with special needs.
  • Based on sterility, the sterile segment dominated the market with the largest revenue share in 2023 due to the significant demand for intravenous sterile planning required by geriatric and pediatric patients.
  • For instance, in February 2023, Harrow Health, Inc., a prominent U.S. eyecare pharmaceutical company, launched its patent-pending, next-generation compounded Atropine formulations, now accessible through its compounding and mail-order pharmacy subsidiary, ImprimisRx.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Type
    • 1.2.2. Therapeutic Area
    • 1.2.3. Age Cohort
    • 1.2.4. Compounding Type
    • 1.2.5. Sterility
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources & Third-Party Perspectives
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing demand for personalized medications
      • 3.2.1.2. Growing importance of pharmaceutical compounding in promoting medication adherence
      • 3.2.1.3. Increasing supportive government policies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Quality and safety concerns
      • 3.2.2.2. Chances of human errors or medication errors
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenges Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis

Chapter 4. Type Business Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. U.S. Compounding Pharmacies Market: Type Movement Analysis
  • 4.3. U.S. Compounding Pharmacies Market Size & Trend Analysis, by Type, 2018 - 2030 (USD Million)
  • 4.4. 503A
    • 4.4.1. 503A Market, 2018 - 2030 (USD Million)
  • 4.5. 503B
    • 4.5.1. 503B Market, 2018 - 2030 (USD Million)

Chapter 5. Therapeutic Area Business Analysis

  • 5.1. Therapeutic Area Segment Dashboard
  • 5.2. U.S. Compounding Pharmacies Market: Therapeutic Area Movement Analysis
  • 5.3. U.S. Compounding Pharmacies Market Size & Trend Analysis, by Therapeutic Area, 2018 - 2030 (USD Million)
  • 5.4. Pain Management
    • 5.4.1. Pain Management Market, 2018 - 2030 (USD Million)
  • 5.5. Hormone Replacement Therapy
    • 5.5.1. Hormone Replacement Therapy Market, 2018 - 2030 (USD Million)
  • 5.6. Specialty Drugs
    • 5.6.1. Specialty Drugs Market, 2018 - 2030 (USD Million)
  • 5.7. Dermatology
    • 5.7.1. Dermatology Market, 2018 - 2030 (USD Million)
  • 5.8. Nutritional Supplements
    • 5.8.1. Nutritional Supplements Market, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Age Cohort Business Analysis

  • 6.1. Age Cohort Segment Dashboard
  • 6.2. U.S. Compounding Pharmacies Market: Age Cohort Movement Analysis
  • 6.3. U.S. Compounding Pharmacies Market Size & Trend Analysis, by Age Cohort, 2018 - 2030 (USD Million)
  • 6.4. Pediatric
    • 6.4.1. Pediatric Market, 2018 - 2030 (USD Million)
  • 6.5. Adult
    • 6.5.1. Adult Market, 2018 - 2030 (USD Million)
  • 6.6. Geriatric
    • 6.6.1. Geriatric Market, 2018 - 2030 (USD Million)

Chapter 7. Compounding Type Business Analysis

  • 7.1. Compounding Type Segment Dashboard
  • 7.2. U.S. Compounding Pharmacies Market: Compounding Type Movement Analysis
  • 7.3. U.S. Compounding Pharmacies Market Size & Trend Analysis, by Compounding Type, 2018 - 2030 (USD Million)
  • 7.4. Pharmaceutical Ingredient Alteration (PIA)
    • 7.4.1. Pharmaceutical Ingredient Alteration (PIA) Market, 2018 - 2030 (USD Million)
  • 7.5. Currently Unavailable Pharmaceutical Manufacturing (CUPM)
    • 7.5.1. Currently Unavailable Pharmaceutical Manufacturing (CUPM) Market, 2018 - 2030 (USD Million)
  • 7.6. Pharmaceutical Dosage Alteration (PDA)
    • 7.6.1. Pharmaceutical Dosage Alteration (PDA) Market, 2018 - 2030 (USD Million)

Chapter 8. Sterility Business Analysis

  • 8.1. Sterility Segment Dashboard
  • 8.2. U.S. Compounding Pharmacies Market: Sterility Movement Analysis
  • 8.3. U.S. Compounding Pharmacies Market Size & Trend Analysis, by Sterility, 2018 - 2030 (USD Million)
  • 8.4. Sterile
    • 8.4.1. Sterile Market, 2018 - 2030 (USD Million)
  • 8.5. Non Sterile
    • 8.5.1. Non Sterile Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Company Market Position Analysis
  • 9.3. Strategy Mapping
  • 9.4. Company Profiles/Listing
    • 9.4.1. Avella Specialty Pharmacy
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Service Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Central Admixture Pharmacy Services, Inc.
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Service Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Clinigen Limited
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Service Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Fagron
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Service Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. Fresenius Kabi USA
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Service Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. ImprimisRx (Harrow Health, Inc.)
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Service Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. PenCol Pharmacy
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Service Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. Sixth Avenue Medical Pharmacy
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Service Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Triangle Compounding
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Service Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. Vertisis Custom Pharmacy
      • 9.4.10.1. Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Service Benchmarking
      • 9.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. compounding pharmacies market, by type, 2018 - 2030 (USD Million)
  • Table 4 U.S. compounding pharmacies market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 5 U.S. compounding pharmacies market, by age cohort, 2018 - 2030 (USD Million)
  • Table 6 U.S. compounding pharmacies market, by compounding type, 2018 - 2030 (USD Million)
  • Table 7 U.S. compounding pharmacies market, by sterility, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Model details
  • Fig. 8 U.S. Compounding Pharmacies market segmentation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Market dynamics
  • Fig. 13 Market driver relevance analysis (current & future impact)
  • Fig. 14 Market restraint relevance analysis (current & future impact)
  • Fig. 15 PESTLE analysis
  • Fig. 16 Porter's five forces analysis
  • Fig. 17 U.S. compounding pharmacies market: Type outlook and key takeaways
  • Fig. 18 U.S. compounding pharmacies market: Type movement analysis
  • Fig. 19 503A market revenue, 2018 - 2030 (USD Million)
  • Fig. 20 503B market revenue, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. compounding pharmacies market: Therapeutic area outlook and key takeaways
  • Fig. 22 U.S. compounding pharmacies market: Therapeutic area movement analysis
  • Fig. 23 Hormone replacement therapy market revenue, 2018 - 2030 (USD Million)
  • Fig. 24 Pain management market revenue, 2018 - 2030 (USD Million)
  • Fig. 25 Specialty drugs market revenue, 2018 - 2030 (USD Million)
  • Fig. 26 Dermatology market revenue, 2018 - 2030 (USD Million)
  • Fig. 27 Nutritional supplements market revenue, 2018 - 2030 (USD Million)
  • Fig. 28 Others market revenue, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. compounding pharmacies market: Age cohort outlook and key takeaways
  • Fig. 30 U.S. compounding pharmacies market: Age cohort movement analysis
  • Fig. 31 Pediatric market revenue, 2018 - 2030 (USD Million)
  • Fig. 32 Adult market revenue, 2018 - 2030 (USD Million)
  • Fig. 33 Geriatric market revenue, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. compounding pharmacies market: Compounding type outlook and key takeaways
  • Fig. 35 U.S. compounding pharmacies market: Compounding type movement analysis
  • Fig. 36 Pharmaceutical Ingredient Alteration (PIA) market revenue, 2018 - 2030 (USD Million)
  • Fig. 37 Currently Unavailable Pharmaceutical Manufacturing (CUPM) market revenue, 2018 - 2030 (USD Million)
  • Fig. 38 Pharmaceutical Dosage Alteration (PDA) market revenue, 2018 - 2030 (USD Million)
  • Fig. 39 Others market revenue, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. compounding pharmacies market: Sterility outlook and key takeaways
  • Fig. 41 U.S. compounding pharmacies market: Sterility movement analysis
  • Fig. 42 Sterile market revenue, 2018 - 2030 (USD Million)
  • Fig. 43 Non sterile market revenue, 2018 - 2030 (USD Million)
  • Fig. 44 Company categorization
  • Fig. 45 Company market position analysis
  • Fig. 46 Strategy mapping